PuraPharm Corporation Limited announced unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months, the company reported revenue of HKD 212.249 million against HKD 186.902 million a year ago. Profit before tax was HKD 10.386 million against loss before tax of HKD 5.241 million a year ago. Profit for the period was HKD 8.285 million against loss of HKD 7.596 million a year ago. Profit attributable to owners of the parent was HKD 8.285 million or 3.7 cents per basic and diluted share against loss attributable to owners of the parent of HKD 7.596 million or 4.5 cents per basic and diluted share a year ago. Net cash flows used in operating activities were HKD 40.275 million against HKD 10.591 million a year ago. Purchases of items of property, plant and equipment was HKD 21.632 million against HKD 10.209 million a year ago. Purchase of intangible assets was HKD 13.493 million against HKD 2.692 million a year ago.